CN1160080C - 褐藻胶寡糖作为制备预防因东莨菪碱所致痴呆药物的应用 - Google Patents
褐藻胶寡糖作为制备预防因东莨菪碱所致痴呆药物的应用 Download PDFInfo
- Publication number
- CN1160080C CN1160080C CNB011275332A CN01127533A CN1160080C CN 1160080 C CN1160080 C CN 1160080C CN B011275332 A CNB011275332 A CN B011275332A CN 01127533 A CN01127533 A CN 01127533A CN 1160080 C CN1160080 C CN 1160080C
- Authority
- CN
- China
- Prior art keywords
- activity
- group
- algin oligosaccharide
- oligosaccharide
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 29
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 21
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 19
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 19
- 230000002205 anti-dementic effect Effects 0.000 title 1
- 230000003005 anti-senility effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 21
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 16
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 16
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 16
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 16
- 229960002646 scopolamine Drugs 0.000 claims description 16
- -1 mannuronic acid oligosaccharide Chemical class 0.000 claims description 9
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 4
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 36
- 241000699670 Mus sp. Species 0.000 abstract description 14
- 102000010909 Monoamine Oxidase Human genes 0.000 abstract description 13
- 108010062431 Monoamine oxidase Proteins 0.000 abstract description 13
- 206010012289 Dementia Diseases 0.000 abstract description 7
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract description 3
- 229960004373 acetylcholine Drugs 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 150000003254 radicals Chemical class 0.000 abstract description 3
- 102100023460 Choline O-acetyltransferase Human genes 0.000 abstract description 2
- 108010058699 Choline O-acetyltransferase Proteins 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 210000003710 cerebral cortex Anatomy 0.000 abstract description 2
- 210000002569 neuron Anatomy 0.000 abstract description 2
- 239000002858 neurotransmitter agent Substances 0.000 abstract description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000031836 visual learning Effects 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 description 19
- 229920001282 polysaccharide Polymers 0.000 description 19
- 239000005017 polysaccharide Substances 0.000 description 19
- 210000004556 brain Anatomy 0.000 description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 102000019197 Superoxide Dismutase Human genes 0.000 description 12
- 108010012715 Superoxide dismutase Proteins 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 6
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000013016 learning Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012347 Morris Water Maze Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000000225 synapse Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical group ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HGMITUYOCPPQLE-IBGZPJMESA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound O([C@@H]1C2CCN(CC2)C1)C(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 HGMITUYOCPPQLE-IBGZPJMESA-N 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011275332A CN1160080C (zh) | 2001-10-01 | 2001-10-01 | 褐藻胶寡糖作为制备预防因东莨菪碱所致痴呆药物的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011275332A CN1160080C (zh) | 2001-10-01 | 2001-10-01 | 褐藻胶寡糖作为制备预防因东莨菪碱所致痴呆药物的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1408360A CN1408360A (zh) | 2003-04-09 |
CN1160080C true CN1160080C (zh) | 2004-08-04 |
Family
ID=4667475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB011275332A Expired - Fee Related CN1160080C (zh) | 2001-10-01 | 2001-10-01 | 褐藻胶寡糖作为制备预防因东莨菪碱所致痴呆药物的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1160080C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106349298A (zh) * | 2015-07-17 | 2017-01-25 | 上海绿谷制药有限公司 | 褐藻胶寡糖及其衍生物在改善睡眠障碍中的应用 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1562050A (zh) | 2004-03-24 | 2005-01-12 | 中国海洋大学 | 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用 |
CN100372542C (zh) * | 2004-04-16 | 2008-03-05 | 中国海洋大学 | 褐藻胶低聚糖作为益生元的应用 |
CN102488697B (zh) * | 2011-12-09 | 2013-03-20 | 中国海洋大学 | 一种寡聚甘露糖醛酸在制备抗甲型h1n1流感病毒药物中的应用 |
CN103340881B (zh) * | 2013-07-09 | 2016-06-08 | 中国科学院上海药物研究所 | 一种寡糖类化合物在神经保护方面的应用 |
CN103405468B (zh) * | 2013-08-16 | 2015-08-19 | 中国海洋大学 | 一种低分子量甘露糖醛酸寡糖在制备预防或治疗帕金森症的药物或保健品中的应用 |
FR3024358B1 (fr) * | 2014-08-01 | 2017-11-10 | Soc De Courtage Et De Diffusion Codif Int | Compositions cosmetiques et complements alimentaires neuro-protecteurs comprenant de l'oligoalginate ayant un degre de polymerisation de 10 pour lutter contre le vieillissement de la peau. |
CN106344593B (zh) * | 2015-07-17 | 2020-01-10 | 上海绿谷制药有限公司 | 褐藻胶寡糖及其衍生物在制备治疗血管性痴呆药物中的应用 |
CN112336859A (zh) * | 2019-08-06 | 2021-02-09 | 上海绿谷制药有限公司 | 通过抑制t细胞摄取氨基酸治疗阿尔茨海默病的方法 |
CN112336861A (zh) * | 2019-08-06 | 2021-02-09 | 上海绿谷制药有限公司 | 通过调节氨基酸水平治疗阿尔茨海默病的方法 |
CN110882264B (zh) * | 2019-11-13 | 2021-03-26 | 青岛海洋生物医药研究院股份有限公司 | 一种天麻素和甘露糖醛酸寡糖的药物组合物及其用途 |
-
2001
- 2001-10-01 CN CNB011275332A patent/CN1160080C/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106349298A (zh) * | 2015-07-17 | 2017-01-25 | 上海绿谷制药有限公司 | 褐藻胶寡糖及其衍生物在改善睡眠障碍中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1408360A (zh) | 2003-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1160080C (zh) | 褐藻胶寡糖作为制备预防因东莨菪碱所致痴呆药物的应用 | |
CN1562050A (zh) | 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用 | |
Wang et al. | Polyketide glycosides from Bionectria ochroleuca inhibit Candida albicans biofilm formation | |
Cuenca-Bermejo et al. | Cardiac changes in Parkinson’s disease: lessons from clinical and experimental evidence | |
Navarro et al. | Central activation of Alpha7 nicotinic signaling attenuates lps-induced neuroinflammation and sickness behavior in adult but not in aged animals | |
Shao et al. | Carbon nanoparticles inhibit α-glucosidase activity and induce a hypoglycemic effect in diabetic mice | |
Pasquinucci et al. | LP1 and LP2: Dual-target MOPr/DOPr ligands as drug candidates for persistent pain relief | |
de Bartolomeis et al. | Canonical and non-canonical antipsychotics’ dopamine-related mechanisms of present and next generation molecules: a systematic review on translational highlights for treatment response and treatment-resistant schizophrenia | |
Tsapakis et al. | Novel compounds in the treatment of schizophrenia—a selective review | |
Kostennikov et al. | A comparative study of mesenchymal stem cell-derived extracellular vesicles’ local and systemic dose-dependent administration in rat spinal cord injury | |
Xie et al. | Toxicity analysis of mesoporous polydopamine on intestinal tissue and microflora | |
CN1775215A (zh) | 盐酸阿扎司琼葡萄糖注射液制剂、制备方法及其质量控制技术 | |
Kleczkowska | Chimeric structures in mental illnesses—“Magic” molecules specified for complex disorders | |
CN1830428A (zh) | 一种阿魏酸钠注射液及其制备方法和用途 | |
CN101077372A (zh) | 一种用于防治缺铁性贫血的中药组合物及其制备方法 | |
Mezhlumyan et al. | Antidepressant-like effects of BDNF and NGF individual loop dipeptide mimetics depend on the signal transmission patterns associated with trk | |
CN1739530A (zh) | 一种注射用赖氨匹林 | |
CN1254245C (zh) | 羟喜树碱乳剂及其制备方法 | |
Chen et al. | Colon-Targeted Delivery of Indole Acetic Acid Helps Regulate Gut Motility by Activating the AHR Signaling Pathway | |
CN101559069A (zh) | 5’核苷酸在制备缓解体力疲劳药物、保健食品中的用途 | |
CN1771992A (zh) | 一种脑提取物及其制备方法和用途 | |
Bi et al. | Progress in the study of intestinal microbiota involved in morphine tolerance | |
Schreiber et al. | Treatment-Resistant Depression (TRD): Is the Opioid System Involved? | |
CN101053587A (zh) | 一种用于抗肿瘤的药物组合物及制备方法和质量控制方法 | |
Chai et al. | A Prospective, Randomized, Placebo-Controlled Study Assessing the Efficacy of Chinese Herbal Medicine (Huangqi Guizhi Wuwu Decoction) in the Treatment of Albumin-Bound Paclitaxel-Induced Peripheral Neuropathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: QINGDAO OCEAN UNIVERSITY OF CHINA HOLDINGS CO., LT Free format text: FORMER OWNER: OCEAN UNIVERSITY OF CHINA Effective date: 20130527 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: OCEAN UNIVERSITY OF CHINA Free format text: FORMER NAME: QINGDAO OCEANOLOGY UNIV. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266003 QINGDAO, SHANDONG PROVINCE TO: 266071 QINGDAO, SHANDONG PROVINCE |
|
CP01 | Change in the name or title of a patent holder |
Address after: 266003 No. 5 fish Hill Road, Shandong, Qingdao Patentee after: OCEAN University OF CHINA Address before: 266003 No. 5 fish Hill Road, Shandong, Qingdao Patentee before: Ocean University of China |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130527 Address after: 266071 Hongkong East Road, Laoshan District, Shandong, China, No. 23, No. Patentee after: Qingdao Ocean University of China Holdings Ltd. Address before: 266003 No. 5 fish Hill Road, Shandong, Qingdao Patentee before: Ocean University of China |
|
ASS | Succession or assignment of patent right |
Owner name: QINGDAO HAIDA HAITANG BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: QINGDAO OCEAN UNIVERSITY OF CHINA HOLDINGS CO., LTD. Effective date: 20131014 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266071 QINGDAO, SHANDONG PROVINCE TO: 266061 QINGDAO, SHANDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131014 Address after: 1704 room 182-6, Fortune Tower, No. 266061 Haier Road, Laoshan District, Shandong, Qingdao Patentee after: QINGDAO HAIDA HAITANG BIOTECH CO.,LTD. Address before: 266071 Hongkong East Road, Laoshan District, Shandong, China, No. 23, No. Patentee before: Qingdao Ocean University of China Holdings Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20030409 Assignee: QINGDAO BZ OLIGO BIOTECH Co.,Ltd. Assignor: QINGDAO HAIDA HAITANG BIOTECH CO.,LTD. Contract record no.: 2014370000031 Denomination of invention: Use of algin oligosaccharide in anti-senility and anti-dementia Granted publication date: 20040804 License type: Exclusive License Record date: 20140324 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040804 Termination date: 20201001 |
|
CF01 | Termination of patent right due to non-payment of annual fee |